Court rules in favor of Watson in generic Fentora patent suit
MORRISTOWN, N.J. — A generic painkiller made by Watson Pharmaceuticals does not infringe on the patent covering the branded version, a U.S. District Court has ruled.
Watson said the U.S. District Court for the District of Delaware ruled that Watson’s generic version of Cephalon’s Fentora (fentanyl buccal tablets) does not infringe on two patents that were set to expire in March 2019, according to Food and Drug Administration records.
The FDA already had approved Watson’s version of the drug, though a third patent, U.S. Patent No. 6,264,981, remains in effect, preventing Watson’s launch of the drug.
The Apothecary Shops announces 18th store opening
AUSTIN, Texas — Specialty pharmacy provider The Apothecary Shops has opened its 18th store, the company said Monday.
TAS Specialty Pharmacy, an affiliate of Phoenix-based The Apothecary Shops of Deer Valley, opened a full-service specialty pharmacy with a compounding lab in Austin, Texas. The 2,500-sq.-ft. pharmacy will specialize in cancer, transplants, infectious diseases, fertility, women’s health, pain management, eye diseases and animal health.
“As we move forward with our expansion strategy, we chose Austin because of its consistent growth and tremendous potential,” The Apothecary Shops president Keith Cook said. “Our research also indicated that our specialty focus would be a good fit for the community.”
Yost leaves helm of AmerisourceBergen
VALLEY FORGE, Pa. — AmerisourceBergen Monday afternoon announced that CEO David Yost will retire from the wholesaler, effective July 1, after 37 years with the company and the last 14 as CEO.
Yost will be succeeded by Steven Collis, 49.
"Ten years after we announced the merger that created AmerisourceBergen, I am announcing my plans to retire," Yost said. "With our strong position in the growth areas of the pharmaceutical supply chain, generics and specialty pharmaceuticals, I believe [AmerisourceBergen] is exceptionally well-positioned for continued success, and that the company’s future has never been brighter.”
Collis, a 17-year AmerisourceBergen veteran, currently is president and COO, responsible for all AmerisourceBergen business units, including AmerisourceBergen Drug Corp., AmerisourceBergen Specialty Group, AmerisourceBergen Consulting Services and AmerisourceBergen Packaging Group. Before being promoted to his current position in November 2010, Collis was EVP AmerisourceBergen and president of ABDC, the wholesaler’s largest subsidiary with revenues of more than $60 billion. Collis originally helped found ABSG and was the driving force behind growing the business into a $16 billion business.
"Steve’s experience and skills make him eminently qualified to be the next CEO of AmerisourceBergen," Yost said. "The company has great momentum, a seasoned and proven management team and a superb customer-focused, cost-conscious culture. I have no doubts that Steve will continue to grow our business and provide value to our customers, suppliers, shareholders and our associates."